Anticoagulation prophylaxis practice patterns in patients having total hip, total knee replacement in a US health plan

Formulary

Volumn 46, Issue 11, 2011, Pages 486-500

  Baser, Onur ^a   Wang, Li ^b   Supina, Dylan ^c   Sengupta, Nishan ^c  

^a UNIVERSITY OF MICHIGAN   (United States)

^b TATinMED Research   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CONTROLLED STUDY; HEALTH CARE PLANNING; HEALTH CARE PRACTICE; HOSPITAL PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; OUTPATIENT CARE; RISK ASSESSMENT; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM;

EID: 84863167433     PISSN: 1082801X     EISSN: 19381166     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence -Based-Clinical Practice Guidelines (8t h Edition). Chest. 2008;133:381S-453S.
2. Kearon C. Duration of venous thromboembolism prophylax is a fter surgery. Chest. 2003;12 4:386S- 392S.
3. Bartley MK. Keep venous thromboembolism at b ay. Nursing. 2006;36:36-41.
4. Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism. Adherence to the 1995 American College of Chest Physicians Consensus Guidelines for Surgical Patients. Arch Intern Med. 2000;160:334-340.
5. Tapson VF, Hyers TM, Waldo AL, et al, for the NABOR (National Anticoagulation Benchmark and Outcomes Report) Steering Committee. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med. 2005;165:1458-1464.
6. Amin AN, Lin J, Ryan A. Need to improve thromboprophylaxis across the continuum of care for surgical patients. Adv Ther. 2010;27:81-93.
7. Johanson NA, Lachiewicz PF, Lieberman JR, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Bone Joint Surg Am. 2009;91:1756-1757.
8. National Institute for Health and Clinical Excellence. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital. NICE clinical guideline 92. http://www.nice.org.uk/guid-ance/index.jsp?action=byID&o=12695. Accessed May 24, 2011.
9. Parvizi J, Azzam K, Rothman RH. Deep venous thrombosis prophylaxis for total joint arthroplasty: American Academy of Orthopaedic Surgeons guidelines. J Arthroplasty. 2008;23:2-5.
10. Warwick DF, Friedman RJ, Agnelli GF, Gil-Garay E, Johnson K, FitzGerald G, Turibio FM. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg. 2007;89:799-807.
11. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:160S-198S.
12. Hirsh J, Guyatt G, Alberts GW, et al. Executive Summary. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133:71S-105S.
13. Hyers TM, Agnelli G, Hull RD, Morris TA, Tap-son V. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001;119:176S-193S.
14. Huse D, Curkendall S. Linking person-level inpatient data to longitudinal records. International Society for Pharmacoeconomics and Outcomes Research 12th Annual Congress, 2009, A391.
15. Amin AN, Lin J, Lenhart G, Schulman KL. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. Thromb Haemost. 2009;102:321-326.
16. Baser O, Palmer L, Stephenson J. The estimation power of alternative comorbidity indices. Value Health. 2008;11:946-955.
17. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245-1251.
18. D'Hoore W, Bouckaert A, Tilquin C. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996;49:1429-1433.
19. Baser O, Crown WH, Pollicino C. Guidelines for selecting among different types of bootstraps. Curr Med Res Opin. 2006;22:799-808.
20. Baser O, Supina D, Sengupta N, Wang L. Analysis of anticoagulation bridging therapy for patients undergoing total hip or total knee replacement in a U.S. health plan: real world observations and implications. American Health & Drug Benefits. 2011; In Press.
21. Geerts WH, Pineo GF, Heit JA, Berqvist D, Lassen MR, Colwell CW, Ray JG. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S-400S.
22. Medicare and Medicaid move aggressively to encourage greater patient safety in hospitals and reduce never events. Centers for Medicare & Medicaid Services Website, July 31, 2008. Available at: http://www.cms.hhs.gov/apps/media/press/release.asp?Counter=3219&intNumPerPage=10&checkDate=&checkKey=&srchType=1&numDays=3500&srchOpt=0&srchData=&keywordType=All&chkNewsType=1%2C+2%2C+3%2C+4%2C+5&intPage=&showAll=&pYear=&year=&desc=false&cboOrder=date. Accessed June 21, 2011.
23. Caprini JA, Tapson VF, Hyers TM, et al, for the NABOR Steering Committee. Treatment of venous thromboembolism: adherence to guidelines a nd impact of physician knowledge, at t it udes, and beliefs. J Vasc Surg. 2005;42:726-733.
24. Eriksson BI, Borris LC, Friedman RJ, et al, for the RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
25. Kakkar AK, Brenner B, Dahl OE, et al, for the RECORD2 Investigators. Extended duration ri-varoxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
26. Lassen MR, Ageno W, Borris LC, et al, for the RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.
27. Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-1680.
28. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Harnick P, and the ADVANCE-2 Invest iga-tors. Apixaban versus enoxaparin for throm-boprophylaxis after knee replacement (AD-VANCE-2): a randomised double-blind trial. Lancet. 2010;375:807-815.
29. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361:594-604.
30. Eriksson BI, Dahl OE, Rosencher N, et al, for the RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-956.
31. Eriksson BI, Dahl OE, Rosencher N, et al, for the RE-MODEL Study Group. Oral dabiga-tran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.